ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PDSB / financials
CUE (29) ALXO (44) MGNX (24) NGEN (45) ⌘ Pro Terminal →

PDS Biotechnology Corporation (PDSB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.37 -4.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.36

PDS Biotechnology Corporation (PDSB) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $151.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PDSB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PDSB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, PDS Biotechnology Corporation (NASDAQ: PDSB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.37 (-4.86% 1D, market cap $151.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PDSB ranks #336 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PDSB compare to CUE and ALXO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PDSB carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CUE (Cue Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M) and ALXO (ALX Oncology Holdings Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $152.4M). Among the 5-stock peer group, PDSB leads on earnings multiple (N/A) while PDSB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PDSB?
▼

Per PDSB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001472091), PDS Biotechnology Corporation generated $88.3M in revenue (-13.2% YoY), -$34.5M in net income, and -$27.8M in free cash flow against $30.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.36 (-1.06%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (8)Whales (15)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-5.1% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE PDSB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PDSB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY PDSB SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$1.60-40% Next Q
Q2 (-2Q)
51
Grade C-$0.96+35.4% Next Q
Q3 (-1Q)
49
Grade D$1.30+5.4% Next Q
Current
46
Grade D$1.37-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PDSB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PDSB currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.85) and Max Pain ($1.44) forces dealer call-delta covering toward $1.88.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PDSB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PDSB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PDSB Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$88.3MGross Profit $45.9M (52%)Cost of Sales $42.4MOp Profit $0 (0%)OpEx (R&D/SG&A) $45.9MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $120.5M
FY24
Rev $101.7M
FY25
Rev $88.3M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$88.3M52%-35.7%-$34.5M-$27.8M-45%
FY 2024$101.7M52%-35.7%-$37.6M-$35.1M-45%
FY 2023$120.5M52%-35.7%-$42.9M-$33.6M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PDSB)

  • ✓Walkthrough of PDSB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PDSB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.00%📐 HORIZONTAL RANGE
2026-11-03O $1.55H $1.55L $1.37C $1.37VOL 5.55M
RES: $1.88SUP: $-0.49SMA50: $0.85SMA200: $0.83
$1.90$1.44$0.97$0.51$0.05RES $1.88SUP $-0.49$1.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PDSB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PDSB Butterfly Map → + Track PDSB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -13.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PDSB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PDSB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PDSB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PDSB)

Health Care Rank #336 of 1015 ⚔️ CUE vs PDSB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PDSB vs. CUE, ALXO, MGNX, NGEN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PDS Biotechnology Corporation (PDSB) ranks #336 by composite RQD confidence (46/100, grade D) and #604 by equity capitalization ($151.2M). Within this direct 5-issuer industry benchmark cohort, PDSB leads on earnings valuation at N/A trailing P/E, while PDSB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PDSB currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PDSB ACTIVE
PDS Biotechnology Corporation
D 46/100 — — -35.0% -4.86% $151.2M Benchmark Subject
CUE
Cue Biopharma Inc.
E 29/100 — — -35.0% -6.95% $151.6M /cue-vs-pdsb →
ALXO
ALX Oncology Holdings Inc.
D 44/100 — — -35.0% +12.30% $152.4M /alxo-vs-pdsb →
MGNX
MacroGenics Inc.
E 24/100 — 96.0% -35.0% -2.92% $152.9M /mgnx-vs-pdsb →
NGEN
NervGen Pharma Corp.
D 45/100 — — — -1.46% $147.4M /ngen-vs-pdsb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001472091 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PDS Biotechnology Corporation (PDSB) reported GAAP revenue of $88.3M (-13.2% vs. FY2024 revenue of $101.7M , and -26.7% cumulative change since FY2023) , GAAP net income of -$34.5M, operating cash flow of -$27.8M, and free cash flow of -$27.8M (+20.8% YoY). On the balance sheet, PDSB closed FY2025 with $30.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $88.3M -$34.5M -$27.8M -$27.8M $30.5M —
FY2024 (FY) 2024-12-31 $101.7M -$37.6M -$35.0M -$35.1M $45.4M —
FY2023 (FY) 2023-12-31 $120.5M -$42.9M -$33.6M -$33.6M — —

3. PDSB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PDSB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PDS Biotechnology Corporation (NASDAQ: PDSB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.37 (-4.86% 1D, market cap $151.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PDSB ranks #336 in composite RQD confidence.

How does PDSB compare to CUE and ALXO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PDSB carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CUE (Cue Biopharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M) and ALXO (ALX Oncology Holdings Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $152.4M). Among the 5-stock peer group, PDSB leads on earnings multiple (N/A) while PDSB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PDSB?

Per PDSB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001472091), PDS Biotechnology Corporation generated $88.3M in revenue (-13.2% YoY), -$34.5M in net income, and -$27.8M in free cash flow against $30.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PDSB trading relative to its 50-day, 200-day, and 52-week technical levels?

PDSB last traded at $1.37 (-4.86% on volume of 4,122,539 shares), positioning the stock +61.18% above its 50-day simple moving average ($0.85) and +65.06% above its 200-day simple moving average ($0.83). Across its 52-week range of $0.19 to $1.79, PDSB sits at the 73.8% percentile with a 14-day RSI of 60.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).

Direct Sub-Reports: PDSB RQD Cockpit PDSB 12M Forecast PDSB Earnings & Move PDSB Dividends & DRIP PDSB Insiders & 13F PDSB Whale Options PDSB Profit Sankey PDSB News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

PDSB — PDS Biotechnology Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PDS Biotechnology Corporation (PDSB) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.37 (-4.86% 1D, market capitalization $151.2M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -17.05%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

PDS Biotechnology Corporation (PDSB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PDS Biotechnology Corporation (PDSB) reported $88.3M in annual revenue (up from $101.7M in FY2024, -13.2% YoY) and -$34.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($120.5M revenue, -$42.9M net income) through FY2025, PDSB scaled operating cash flow to -$27.8M and free cash flow to -$27.8M, backed by $30.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -17.05% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $0.19 – $1.79 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should note that the absence of mapped links means this dossier cannot identify ripple effects from partners, suppliers, or customers.

  • Key Question #1: Can PDSB sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $88.3M and free cash flow of -$27.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PDSB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PDSB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PDS Biotechnology Corporation (PDSB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PDSB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PDSB Bull vs. Bear Conversation Board — What's Your Call at $1.37?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PDSB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PDSB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $1.84 (+27.8%)
📌 Pinned Debate

Whale 13F Flow scores 12/20 on institutional accumulation and options positioning, and the stock trades near the top of its $1.35–$1.69

Picked up a starter position in PDSB in my $100K Virtual Cash book at $1.44. Whale 13F Flow scores 12/20 on institutional accumulation and options positioning, and the stock trades near the top of its $1.35–$1.69 52-week range at $1.55.. Trading inside a $0.26–$1.79 52-week range with -17.05% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 46/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.44 and keeping dry powder in case we test $1.34.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $1.20 (-16.7%)
Spot @ $1.44

Reported ROIC of -35% and FCF yield of -17.05% alongside FY 2025 FCF of -$27.8M against cash of $26.7M point to ongoing cash burn with

Reported ROIC of -35% and FCF yield of -17.05% alongside FY 2025 FCF of -$27.8M against cash of $26.7M point to ongoing cash burn with limited balance sheet cushion.. Look at the math on PDSB: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.27 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%